A detailed history of Arizona State Retirement System transactions in Rhythm Pharmaceuticals, Inc. stock. As of the latest transaction made, Arizona State Retirement System holds 13,168 shares of RYTM stock, worth $740,436. This represents 0.0% of its overall portfolio holdings.

Number of Shares
13,168
Previous 12,627 4.28%
Holding current value
$740,436
Previous $518,000 33.01%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$40.81 - $55.0 $22,078 - $29,755
541 Added 4.28%
13,168 $689,000
Q2 2024

Aug 05, 2024

SELL
$35.41 - $44.37 $12,960 - $16,239
-366 Reduced 2.82%
12,627 $518,000
Q1 2024

May 07, 2024

BUY
$39.12 - $52.44 $10,445 - $14,001
267 Added 2.1%
12,993 $562,000
Q4 2023

Jan 24, 2024

SELL
$21.39 - $49.64 $4,791 - $11,119
-224 Reduced 1.73%
12,726 $585,000
Q3 2023

Nov 06, 2023

BUY
$15.81 - $27.8 $3,146 - $5,532
199 Added 1.56%
12,950 $296,000
Q2 2023

Aug 01, 2023

SELL
$16.32 - $21.15 $5,059 - $6,556
-310 Reduced 2.37%
12,751 $210,000
Q1 2023

Apr 27, 2023

BUY
$16.88 - $34.24 $27,210 - $55,194
1,612 Added 14.08%
13,061 $233,000
Q4 2022

Feb 07, 2023

BUY
$22.21 - $30.25 $26,163 - $35,634
1,178 Added 11.47%
11,449 $333,000
Q3 2022

Nov 07, 2022

BUY
$4.3 - $30.85 $176 - $1,264
41 Added 0.4%
10,271 $252,000
Q2 2022

Jul 28, 2022

BUY
$3.12 - $12.25 $31,917 - $125,317
10,230 New
10,230 $42,000
Q2 2021

Aug 02, 2021

SELL
$18.52 - $22.55 $185,700 - $226,108
-10,027 Closed
0 $0
Q1 2021

May 06, 2021

BUY
$20.25 - $39.49 $60,466 - $117,917
2,986 Added 42.41%
10,027 $213,000
Q4 2020

Jan 28, 2021

BUY
$21.17 - $32.61 $149,057 - $229,607
7,041 New
7,041 $209,000

Others Institutions Holding RYTM

About RHYTHM PHARMACEUTICALS, INC.


  • Ticker RYTM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,720,000
  • Market Cap $3.13B
  • Description
  • Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convert...
More about RYTM
Track This Portfolio

Track Arizona State Retirement System Portfolio

Follow Arizona State Retirement System and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Arizona State Retirement System, based on Form 13F filings with the SEC.

News

Stay updated on Arizona State Retirement System with notifications on news.